Skip to content

The efficacy of Buspirone on withdrawal symptoms in children and adolescents with substance use disorder on treatment with buprenorphine

The efficacy of Buspirone on withdrawal symptoms in children and adolescents with substance use disorder on treatment with buprenorphine

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20110411006168N5
Enrollment
40
Registered
2023-04-29
Start date
2022-10-23
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid Use Disorders. Opioid abuse

Interventions

Intervention 1: Intervention group: After emergence of withdrawal symptoms, an average of 2 mg of buprenorphine is started in two divided doses and if needed, 2 mg of buprenorphine up to a maximum of

Sponsors

Kerman University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 18 Years

Inclusion criteria

Inclusion criteria: Diagnosis of opioid use disorder based on DSM-5 by a child and adolescent psychiatrist age 5-18 years old

Exclusion criteria

Exclusion criteria: Allergy to buprenorphine orBuspirone. .Chronic or inflammatory diseases (heart, lung, liver, kidney or neurological diseases such as epilepsy) Serious psychiatric illnesses such as schizophrenia and other psychotic disorders, acute phase of bipolar disorder and moderate to severe mental disability Dissatisfaction of the patient's parent or Legal guardian to continue the plan.

Design outcomes

Primary

MeasureTime frame
Withdrawal symptoms according to psychiatrist examination and patient report. Timepoint: days 1 to 14. Method of measurement: Clinical opioid withdrawal scale and subjective opioid withdrawal scale.

Secondary

MeasureTime frame
Drug side effects. Timepoint: day 1 to 14. Method of measurement: Checklist of drug side effects.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mahin Eslami Sharbabaki

Kerman University of Medical Sciences

m_eslami@kmu.ac.ir+98 34 3211 7623

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026